[ad_1]
LONDON: Oxford University’s COVID-19 vaccine candidate vaccine has a better immune response when a two full dose regimen is used rather than a full dose followed by a half dose booster, the university said Thursday ( December 17), citing data from early trials.
The developers of the candidate vaccine, which has been licensed to the pharmaceutical company AstraZeneca, have already published results from later-stage trials showing greater efficacy when a half dose is followed by a full dose, compared to a two-dose regimen. complete. However, more work is needed to affirm that result.
The latest details from Phase I and 2 clinical trials released Thursday made no reference to the half-dose / full-dose regimen, which Oxford has said was not “planned” but approved by regulators.
Once seen as the pioneer in the development of a coronavirus vaccine, the British team has been overtaken by US drugmaker Pfizer, whose vaccines have been rolled out in the UK and US this month.
READ: Pfizer-BioNTech, Moderna and Sinovac: A Look at Three Key COVID-19 Vaccines
Previously published data from the latest phase 3 trials showed that efficacy was 62 percent for trial participants who received two full doses, but 90 percent stronger for a smaller subgroup that received half first and then a full dose.
In its statement Thursday, the university said it had explored two dosing regimens in the early stages of the trials, a full-dose / full-dose regimen and a full-dose / half-dose regimen, investigated as a possible “savings strategy. dose “.
“Booster doses of the vaccine have been shown to induce stronger antibody responses than a single dose, and the standard dose / standard dose induces the best response,” the university said in a statement.
The vaccine “stimulates broad antibody and T-cell functions,” he said.
CHECK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments
Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram
